FOLD · AMICUS THERAPEUTICS, INC.
Market Cap
$4.55B
Shares
314.00M
No Price Data
No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Feb 20, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
Limited
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
55 of 297 funds reported for Jun 30 · net -9.9M sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.98% of float · ▲ +3.9% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
297 holders — mid 3-yr range
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
89%
contracting
EPS growth
+50%
Y/Y
Free cash flow
$29.8M
Balance sheet
$178.7M
net debt
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2025
Combined sales
· 2028
Initiated
$1B
prior FY $634.21M
midpoint +57.7% Y/Y
Guided vs delivered
· last 1 settled
Pombiliti and Opfolda global sales
full year 2024
guided $69M – $71M
$528.3M
Beat +654.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP net income non-GAAP | $31.6M | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FOLD
this stock
AMICUS THERAPEUTICS, INC.
|
$4.55B | — | +20.0% | — | 7.0% |
|
ONC
BeOne Medicines Ltd.
|
$453.48B | +7.8% | +22179.2% | 697.3 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$119.47B | +6.9% | +46.2% | 27.5 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$78.17B | -0.2% | +20.8% | 18.8 | 3.4% |
|
ARGX
Argenx SE
|
$54.30B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events